OBJecTIve: Post-transplant anemia is a common complication in renal allograft recipients. The most common causes are impaired graft function, immunosuppressive drugs, and infections. The aim of our study was to further investigate the prevalence of anemia before and after renal transplantation in renal allograft recipients in Turkey.
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INTRODUCTION
Following renal transplantation (RT), erythropoiesis begins and the erythropoietin (EPO) level increases to a sustained level in a month. However, while anemia develops in some renal allograft recipients, the existing anemia persists following transplantation in others. The causes of anemia in renal allograft recipients are acute and chronic allograft dysfunction, use of immunosuppressive drugs such as azathioprine and mycophenolate mofetil, high parathyroid hormone levels, infections such as CMV (cytomegalovirus), ACE (angiotensin converting enzyme) inhibitors and ARB (angiotensin receptor blockers) agents, iron deficiency anemia and perioperative blood loss.
The most important risk factor among these is the impaired renal graft function. When the serum creatinine level rises above 2 mg/dl; it results in reduced EPO production and subsequent anemia. It takes 3 months after renal transplantation to evaluate renal anemia because of non-renal reasons such as perioperative blood loss, frequent phlebotomies and fluid shifts interfere with proper evaluation up until 3 months postengraftment (1) . In this study, we aimed to further investigate the prevalence of anemia before and after renal transplantation in renal allograft recipients in Turkey.
MATERIAL and METHODS
The current study included a total of 464 patients who received a kidney transplant between 06/01/2010 and 07/27/2012. All the patients had been on regular outpatient follow-up at Akdeniz University Organ Transplant Institute, which is a nationwide transplantation center. During the study, the prevalence of anemia in patients after renal transplantation was evaluated at the 3rd and 6th months. The World Health Organization (WHO) criteria of a hemoglobin (Hgb) <13 g/dL in men, <12 g/dL in women and <11g/dL in children were used to define anemia Our study is a retrospective study.
RESULTS
Prior to the transplant surgery, 78.8% of the patients had anemia (80.4% of the men, 76% of the women). At the 3rd month of post-transplantation, 37.5% of the patients had anemia. 35.6% of male allograft recipients and 40.8% of female allograft recipients had anemia at the 3rd month after transplantation. On the other hand, the prevalence of anemia decreased to 28.4% 6 months after the transplant surgery, when 28.8% of the men and 27.7% of the women had anemia (Table I) .
Of the patients who did not have anemia before the kidney transplantation, 19.3% developed anemia 3 months after the transplantation; while 24.4% developed anemia 6 months after the transplantation. 17,8% of women with no anemia prior to the transplantation developed anemia 6 months after the surgery; while 28.9% of men with no anemia prior to the transplantation developed anemia 6 months after the transplant surgery (Table II) .
DISCUSSION
Anemia in kidney transplant recipients is a topic of increasing interest. The prevalence of anemia has also been found to be really high in functional renal transplant patients. There are various data in the literature on the prevalence of anemia after renal transplantation. Elsayed et al reported that the prevalence of anemia was 74% three months after renal transplantation, and 45% six months after renal transplantation (2). Vanrenterghem et al reported that the prevalence of post-transplantation anemia was 38% in the first year after the transplant surgery (3). We found that the prevalence of anemia was 37.5% and 28.4% at the Previous studies suggest that anemia can raise the risk of cardiovascular events in patients on hemodialysis, and cardiovascular diseases have been reported as the primary cause of death in kidney transplant recipients (4) . In this regard, renal allograft recipients with anemia should be treated promptly in a manner similar to normal healthy patients. For the treatment of anemia in renal allograft recipients, iron replacement therapy should be used if the patient has iron deficiency and EPO (erythropoetin) therapy should be administered if impaired renal function exists, which are the routine procedures for the treatment of anemia in non-transplant patients and should not be overlooked.
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